EP59: Consultation With A Patient That Doesn't Want To Take Statins

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Summary Introduction Dr. Warrick Bishop, a practicing cardiologist and author, hosts a consultation with his patient Michael, a 72-year-old previously fit and active man who recently suffered a heart attack and received a stent placement in his LAD artery. The episode focuses on addressing Michael's significant apprehension about taking statin therapy, which stems largely from misinformation he encountered online about statins and dementia. Key Takeaways: Michael's reluctance to take statins is primarily driven by fear that they cause cognitive decline and dementia, based on research he found on YouTube and the internet rather than medical evidence. The FDA conducted a thorough review of statins and found absolutely no evidence from clinical trials that they cause any decrease in mental cognition, despite investigating concerns about memory issues. Statins likely do not affect brain cholesterol because they do not cross the blood-brain barrier, and newborns naturally have LDL cholesterol levels of 0.6-0.7 mmol/L—far lower than typical adult levels—without developmental problems. Statins may actually help prevent dementia indirectly by reducing vascular events (strokes and mini-strokes caused by cholesterol buildup in brain arteries), which are a significant cause of dementia. Internet information about statins is often biased and disproportionately amplified by individuals with financial interests in creating controversy, whereas peer-reviewed medical evidence and professional guidelines are based on rigorous research. In secondary prevention cases like Michael's (after a cardiac event), lowering cholesterol through statins is supported by extensive evidence to stabilize plaque and reduce future cardiac events. Idiosyncratic side effects to statins do exist in some patients, but these are not dose-related and are not replicated across the broader patient population, and serious complications like rhabdomyolysis are extremely rare (1 in 70,000). Dr. Bishop does not advocate prescribing statins based solely on cholesterol numbers; he emphasizes the importance of imaging and risk assessment to determine who truly benefits from cholesterol-lowering therapy. Australian lipid guidelines have evolved based on new research, with current secondary prevention targets being an LDL level of 1.8 mmol/L or lower, which Michael's baseline of 2.4 exceeds.